GLP1R and type 2 diabetes mellitus: Similarly, in overweight/obese patients with T2DM, no changes in SMM and SMI were reported following 24 weeks of the DPP-4i teneligliptin (20 mg/daily) compared with the GLP-1 RAs dulaglutide; during the latter drug, a reduction in both the evaluated markers of sarcopenia was observed [68] (Table 1).